Transfection Reagents


Transfection solutions for your R&D activity


We developed broadly acting transfection reagents to modify cells with plasmid DNA and siRNA. The transfection reagents have been optimized so far for the following applications:

Cell Lines:

  • kidney cells (293T)
  • breast cancer cells (MDA231, MDA435 and MCF-7)
  • chronic myeloid leukemia cells (K562)
  • acute myeloid leukemia cells (THP-1 and KG1)
  • acute lymphocytic leukemia cells (NALM-6 and MOLM-13)
  • lymphoma cells (U937)
  • Primary Cells:

  • primary leukocytes
  • fibroblasts
  • smooth muscle cells
  • endothelial cells
  • mesenchymal stem cells (human and rodent derived)
  • Animal models:

  • breast cancer xenograft tumor mice model
  • leukemia xenograft tumor mice model
  • For a classification our transfection reagents by cells type please see our Transfection Reagent Selection Guide For a detailed description of our transfection reagents please see below: Once you decided the right transfection reagent for your application, proceed to our Store

    Transfection Reagents

    ALL-Fect

    This product is designed for transfection of attachment-dependent cells with plasmid DNA and siRNA. It is particularly suitable for mesenchymal stem cells from cord blood and bone marrow, and highly differentiated cells such as smooth muscle cells, and endothelial cells.

    Download ALL-Fect Brochure
    View Product
    Benefits of the reagent :
    • High transfection efficiency
      Provides 2 to 3-fold higher efficacy under serum conditions
    • Simple Protocol
      No need to change tissue culture medium during transfection
    • Toxicity
      Less toxic compared to commercial transfection reagents, leading to better retention of normal cellular physiology
    References :
    • Hsu and Uludağ. Biomaterials (2012) 33: 7834-7848.
    • Remant Bahadur et al., J. Materials Chemistry B (2015) 3: 3972-3982.
    • Wang et al., J. Surgical Research (2013) 183: 8-17.


    Typical performance of All-Fect for transfecting cord-blood derived mesenchymal stem cells with a GFP plasmid. The study compared the performance of All-Fect against a leading lipofection reagent under conditions optimized for each reagent. The extent of transgene expression was quantitated by flow cytometry, based on the extent of EGFP expression in arbitrary units. Typical fluorescent micrographs showing GFP expression after transfection are provided on the top.

    293-Fect

    This product is designed for transfection of attachment dependent and rapidly dividing cells such as 293T cells, with plasmid DNA. These cells are routinely transfected for small scale production of proteins for R&D purposes, as well as industrial scale production of proteins for commercial and clinical uses. This reagent is also effective with other attachment-dependent cells such as CHO cells and breast cancer MDA-231 cells.

    Download 293-Fect Brochure
    View Product
    Benefits of the reagent :
    • High transfection efficiency
      Provides 2 to 3-fold higher efficacy under serum conditions
    • Simple Protocol
      No need to change tissue culture medium during transfection
    • Toxicity
      Less toxic compared to commercial transfecting reagents, leading to better protein yields from the transfected cells
    • Stability
      Long term stability at room temperature
    References :
    • Clements et al., Clinical Orthopeadics and Related Research (2009) 467: 3129-3137.
    • Naemnark et al., Molecular Pharmaceutics (2009) 6: 1798-1815.




    Typical performance of 293-Fect for transfecting attachment-dependent 293 cells with a GFP plasmid is shown in the figure. The study compared the performance of 293-Fect against a leading lipofection reagent and linear PEI (L-PEI; 44 kDa) under conditions optimized for each reagent. Typical fluorescent micrographs showing EGFP expression after transfection (A). The extent of transgene expression was quantitated by flow cytometry, based on the percentage of cells expressing the GFP gene (B) and the extent of GFP expression in arbitrary units (C).

    Leu-Fect-A & B

    These products are designed for transfection of attachment-independent (suspension growing) cells and are specifically tailored for siRNA delivery. We offer two different formulations (Leu-Fect A and Leu Fect B) that are effective in different types of attachment-independent cells. We recommend the users to test the efficacy of both reagents in their particular cell type and choose the right formulation for long-term use.

    Download Leu-Fect-A Brochure
    View Leu-Fect A
    View Leu-Fect B
    Benefits of the reagent :
    • High transfection efficiency
      Provides 2 to 3-fold higher efficacy under serum conditions
    • Simple Protocol
      No need to change tissue culture medium during transfection
    • Toxicity
      Less toxic compared to commercial transfecting reagents, leading to better protein yields from the transfected cells
    References :
    • Gul-Uludag et al. Leukemia Research (2014) 38: 1299–1308.
    • Landry et al. J. Controlled Release (2016) 224: 8-21.
    • Valencia-Serna et al. J. Controlled Release (2013) 172: 495-503.



    Uptake of Leu-Fect/FAM-siRNA complexes in K562 cells in vitro (A) and in vivo K562 tumors (B). Typical performance of Leu-Fect for transfecting K562 chronic myeloid leukemia (CML) cells with a specific siRNA against Bcr-Abl. The study compared the performance of Leu-Fect against a leading lipofection reagent and branched PEI (PEI25; 25 kDa) under conditions optimized for each reagent. The extent of gene silencing was quantitated by qPCR (C). The functional outcome, in the form of inhibition of cell growth, was assessed by the MTT Assay and expressed relative to non-treated cells (D).

    In Vivo DNA-Fect

    This product is designed for delivery of plasmid DNA in animal models. It is a cost-effective alternative to PEI-based reagents marketed for in vivo applications, with improved transfection efficiency. The application of current reagents is usually limited by their toxicity, which either limits the expression of the transgenes or alters the physiological response in the vicinity of the administered agents. The biocompatibility of In Vivo DNA-Fect minimally alters the cellular physiology, allowing a better response of the expressed transgenes.

    Download In Vivo DNA-Fect Brochure
    View Product
    Benefits of the reagent :
    • High transfection efficiency
      Provides 2 to 3-fold higher efficacy under serum conditions
    • Simple Protocol
      Can be administered with simple formulations such as saline
    • Toxicity
      Less toxic compared to commercial transfecting reagents, leading to better protein yields from the transfected cells
    References :
    • Rose et al., Biomaterials Science (2014) 2: 833-842.
    • Rose et al., Biomaterials (2012) 33: 3363-3374.



    Typical performance of In Vivo DNA-Fect for transfecting tissues with two separate GFP plasmids at the rat subcutaneous site is shown in the figure. The study compared the performance of In Vivo DNA-Fect against branched PEI (PEI25; 25 kDa), after the corresponding complexes were implanted in gelatin sponges for 14 days. The extent of transgene expression was assessed by histology of explanted tissues, followed by the fluorescent microscopy.

    In Vivo RNA-Fect

    This product is designed for delivery of siRNA in mice tumor models. It can be directly administered into a specific site (e.g., intratumorally), or systematically. It is a cost-effective alternative to PEI-based reagents marketed for in vivo applications.

    Download In Vivo RNA-Fect Brochure
    View Product
    Benefits of the reagent :
    • High transfection efficiency
      Provides effective transfection under physiological conditions
    • Simple Protocol
      siRNA particles can be prepared in saline suitable for administration
    • Toxicity
      Less toxic compared to other commercial transfecting reagents
    References :
    • Aliabadi et al., J. Controlled Release (2013) 172: 219-228.
    • Alshamsan et al., Translational Oncology (2011) 4: 178-188.
    • Abbasi et al., Pharmaceutical Research (2011) 28: 2516-2529.


    Tumor growth profiles as a result of siRNA delivery with In Vivo RNA-Fect is shown in the figure. The tumors were left untreated, or treated with scrambled and therapeutic siRNAs formulated with the transfection reagent. Formulations injected intratumorally (A). Formulations injected intraperitoneally (B).

    Transfection Reagents for

    Biologics Production


    We developed a specific reagent for transfection of suspension-growing cells for large-scale production of biologics. The transfection reagent allows efficiency transfer of an expression system into cells for transient production of high value-added reagents, such as cytokines and antibodies.
    Product :
    • X

    Delivery Systems for

    Clinical Development


    We are developing novel drug delivery systems to effectively deliver nucleic acids therapeutics in a clinical setting. Our focus is to implement RNA interference (RNAi) via delivery of short interfering RNA. Our therapeutic focus is blood cancers, while recognize that the RNAi activity can be implemented in a large range of human disorders. The R&D activity is at preclinical stage and we are committed to undertake the initial development of our therapeutic agents in select human disorders. For disorders beyond the focus of RJH, we are actively looking for pharmaceutical companies to partner with in specific clinical indications.
    Patient Data :
    • Gul-Uludag et al. Nanoparticle-mediated silencing of CD44 receptor in CD34+ acute myeloid leukemia blasts. Leukemia Research (2014) 38: 1299–1308.
    • Landry et al. Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia. J. Controlled Release (2016) 224: 8-21.